Results 201 to 210 of about 175,167 (244)

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Epistasis regulates genetic control of cardiac hypertrophy. [PDF]

Nat Cardiovasc Res
Wang Q, Tang TM, Youlton M, Weldy CS, Kenney AM, Ronen O, Hughes JW, Chin ET, Sutton SC, Agarwal A, Li X, Behr M, Kumbier K, Moravec CS, Tang WHW, Margulies KB, Cappola TP, Butte AJ, Arnaout R, Brown JB, Priest JR, Parikh VN, Yu B, Ashley EA.   +23 more
europepmc   +1 more source

A comprehensive review of cancer‐induced cardiac wasting

British Journal of Pharmacology, EarlyView.
Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena, Muhammad Shahzeb Khan, Ulrich Keller, Lars Bullinger, Dominik P. Modest, Markus S. Anker   +5 more
wiley   +1 more source

MicroRNA mediated regulation in early-onset cardiac hypertrophy: Insights from the hypertrophic heart rat model. [PDF]

PLoS One
Sadiq S, Charchar FJ, Sanigorski A, Crowley T, Bookun HR, McClure DN.   +5 more
europepmc   +1 more source

The effect of cuproptosis-related gene Atox1 on cardiac hypertrophy in heart failure was investigated based on bioinformatics analysis. [PDF]

Sci Rep
Zhou H, Yang M, Jin H, Ye Z.
europepmc   +1 more source

Cathepsin B in human peripheral blood lymphocytes as a peripheral biomarker for cardiac hypertrophy. [PDF]

Sci Rep
Feng D, Li C, Gao W, Sui Y, Zhao S, Wang Y, Zhang G, Dong Y, Wang J.   +8 more
europepmc   +1 more source

Unlocking Hopeaphenol: A Potent Ally Against Cardiac Hypertrophy via AMPK Activation. [PDF]

Nutrients
Chen J, Wang M, Zhang Z, Fang C, Zhuang H, Zhao J, Wang T, Wang J, Li C, Fang C.   +9 more
europepmc   +1 more source

Case Report: Novel GLA mutation in a Chinese female with renal-predominant Fabry disease and cardiac hypertrophy. [PDF]

Front Genet
Li L, Chang T, Li X, Hao Y, Deng M, Li Y.   +5 more
europepmc   +1 more source

ATF3 overexpression is associated with cardiac hypertrophy and electrical dysfunction accompanied by enhanced cardiac cell proliferation in zebrafish. [PDF]

Sci Rep
Kim E, Kim J, Moon HY, Kim JY, Jeong MH, Kim GY, Lee SH, Kim CH, Kim JW, Kim WH.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cardiac hypertrophy and hypertension

Current Opinion in Nephrology and Hypertension, 1998
In the general population and in patients with essential hypertension the presence of left ventricular hypertrophy is a powerful predictor of cardiovascular events, independent of blood pressure and other cardiovascular risk factors. The prevalence of left ventricular hypertrophy increases with age and with the severity of renal impairment.
AGABITI ROSEI, Enrico, MUIESAN, Maria Lorenza   +1 more
openaire   +3 more sources